Afam Capital Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 82,641 shares of the biopharmaceutical company’s stock after buying an additional 8,056 shares during the quarter. Afam Capital Inc.’s holdings in Pfizer were worth $2,776,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Beaton Management Co. Inc. acquired a new stake in shares of Pfizer during the second quarter worth $1,771,000. Fort Pitt Capital Group LLC boosted its holdings in shares of Pfizer by 0.4% during the second quarter. Fort Pitt Capital Group LLC now owns 200,902 shares of the biopharmaceutical company’s stock worth $6,748,000 after purchasing an additional 825 shares during the last quarter. Raab & Moskowitz Asset Management LLC boosted its holdings in shares of Pfizer by 0.4% during the second quarter. Raab & Moskowitz Asset Management LLC now owns 150,284 shares of the biopharmaceutical company’s stock worth $5,022,000 after purchasing an additional 670 shares during the last quarter. Mountain Capital Investment Advisors Inc acquired a new stake in shares of Pfizer during the second quarter worth $417,000. Finally, Auxier Asset Management boosted its holdings in shares of Pfizer by 0.9% during the second quarter. Auxier Asset Management now owns 85,668 shares of the biopharmaceutical company’s stock worth $2,878,000 after purchasing an additional 800 shares during the last quarter. Hedge funds and other institutional investors own 69.89% of the company’s stock.

Shares of Pfizer Inc. (NYSE PFE) traded up $0.06 during trading on Thursday, reaching $36.64. The company had a trading volume of 15,787,200 shares, compared to its average volume of 19,909,365. Pfizer Inc. has a 52-week low of $30.90 and a 52-week high of $36.82. The firm has a market capitalization of $218,102.86, a PE ratio of 14.64, a P/E/G ratio of 2.58 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter last year, the firm earned $0.61 earnings per share. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. analysts predict that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 3.49%. The ex-dividend date of this dividend was Thursday, November 9th. Pfizer’s payout ratio is currently 79.01%.

In related news, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the transaction, the executive vice president now directly owns 117,432 shares in the company, valued at $4,186,450.80. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.

Several equities research analysts have recently issued reports on PFE shares. Jefferies Group restated a “hold” rating and set a $35.00 price objective on shares of Pfizer in a report on Friday, August 18th. BMO Capital Markets restated a “buy” rating and set a $37.00 price objective on shares of Pfizer in a report on Wednesday, September 6th. Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective on the stock. in a report on Wednesday, September 13th. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Tuesday, September 19th. Finally, Morgan Stanley upgraded Pfizer from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $38.77.

TRADEMARK VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/afam-capital-inc-has-2-78-million-holdings-in-pfizer-inc-pfe/1763839.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with Analyst Ratings Network's FREE daily email newsletter.